The investigators hypothesize that preconditioning neurologically deceased organ donors with
the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival
without causing harm. Organ donors will be randomized to receive either 0.02 mg/kg ideal body
weight (IBW) of tacrolimus single infusion or placebo before organ recovery. All
corresponding recipients are enrolled and data is collected up to 7 days post-transplant to
determine graft function and at 1 year to collect outcomes of vital status,
re-transplantation and dialysis. The CINERGY Pilot Trial assesses feasibility for the main
trial.